Mastocytosis is associated with an activating mutation in the KIT
oncoprotein (KITD816V) that results in autophosphorylation of the KIT receptor in a
ligand-independent manner. This mutation is inherently resistant to
imatinib and, to date, there remains no effective curative
therapy for
systemic mastocytosis associated with KITD816V.
Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple
imatinib-resistant BCR-ABL
isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of
chronic myeloid leukemia (CML). Pharmacokinetic analysis suggests that high nanomolar concentrations of
dasatinib can be achieved safely in humans. In this study, we demonstrate significant inhibitory activity of
dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based
kinase assays. Additionally,
dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line. Significantly,
dasatinib selectively kills primary neoplastic bone marrow mast cells from patients with
systemic mastocytosis while sparing other hematopoietic cells. Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which
imatinib binds, but it is not predicted to impair binding of KIT by
dasatinib. Based upon our results, further evaluation of
dasatinib for the treatment of systemic masto-cytosis in clinical trials is warranted. Moreover,
dasatinib may be of clinical utility in other disease settings driven by activating KIT mutations.